Evommune, Inc. files regulatory documents covering its clinical-stage biotechnology business, public-company governance and capital structure. Its 8-K filings furnish operating and financial results, Regulation FD corporate presentations, material-event disclosures and clinical updates for pipeline programs including EVO756 and EVO301.
Evommune’s SEC record also includes registration materials tied to common stock offerings and proxy materials for annual meeting matters. These filings document director elections, auditor ratification, shareholder voting procedures, capital-structure disclosures, material agreements, clinical and regulatory disclosures, and risk factors associated with developing therapies for chronic inflammatory diseases.
Evommune, Inc., a clinical-stage biotechnology company, reported second quarter 2026 results and highlighted progress across its inflammatory disease pipeline. Lead oral candidate EVO756 is in a fully enrolled Phase 2b trial in moderate-to-severe atopic dermatitis, with top-line data expected in September 2026, and a global Phase 2b migraine prophylaxis trial has recently begun, targeting top-line data in 2027. After a Phase 2b chronic spontaneous urticaria study failed to meet its primary endpoint, development of EVO756 in that indication was discontinued to prioritize atopic dermatitis and migraine. Injectable fusion protein EVO301 showed positive Phase 2a data in atopic dermatitis, with full results to be presented at an upcoming medical conference and a Phase 2b trial planned to start in mid-2027, while additional indications such as ulcerative colitis and certain cardiovascular-related inflammatory conditions are being evaluated.
For the quarter ended June 30, 2026, revenue was zero, research and development expense was $26.4 million, and general and administrative expense was $8.5 million, leading to a net loss of $32.2 million. For the first six months of 2026, net loss was $53.9 million. Cash, cash equivalents and investments totaled $288.0 million as of June 30, 2026, compared with $216.7 million at December 31, 2025, and the company states this provides cash runway through 2028.
Evommune, Inc. reports that the first patient has been dosed in a global Phase 2b clinical trial of its oral MRGPRX2 antagonist EVO756 for prophylactic treatment of migraine. The study targets adults with refractory migraine experiencing at least six migraine days per month.
The randomized, double-blind, placebo-controlled, dose-ranging trial will enroll approximately 330 patients across two active doses and placebo for 12 weeks of daily treatment, exploring doses up to 100 mg. The primary endpoint is change in monthly migraine days, with top-line data expected in 2027.
Point72 Asset Management, L.P., Point72 Capital Advisors, Inc. and Steven A. Cohen report beneficial ownership of 1,910,489 shares of Evommune, Inc. common stock, representing 5.3% of the class as of July 15, 2026. The shares, held by Point72 Associates, carry shared voting and dispositive power only.
The reporting persons state that this statement should not be construed as an admission that they are beneficial owners of these shares for purposes of Section 13 of the Exchange Act.
Evommune, Inc. Chief Financial Officer Kyle Carver purchased 1,000 shares of common stock in an open-market transaction at $13.26 per share, bringing his direct holdings to 60,335 shares. A prior sale of 1,000 shares at $23.42 on May 28, 2026 triggered Section 16(b) short-swing profit rules, and he agreed to pay $10,160 of profit to Evommune.
Evommune, Inc. director Arthur S. Kirsch reported an indirect open-market purchase of 10,000 shares of common stock at a weighted average price of $13.30 per share. The shares are held by a family trust for which he is a trustee, and he disclaims beneficial ownership except for his proportionate pecuniary interest.
Evommune, Inc. furnished a Form 8-K and prospectus supplement reporting top-line results from the randomized, double-blind, placebo-controlled Phase 2b trial of oral MRGPRX2 antagonist EVO756 in adults with moderate-to-severe chronic spontaneous urticaria (CSU). The trial enrolled 160 antihistamine-refractory CSU patients across the United States, Europe, Canada and Japan and tested three active dose regimens versus placebo.
The study did not meet its primary endpoint of mean change in Urticaria Activity Score over seven days (UAS7) at 12 weeks at any dose. Based on these results, the company plans to cease development of EVO756 for CSU while continuing to evaluate the compound in other indications. The press release was issued and furnished as Exhibit 99.1 on June 29, 2026.
Evommune, Inc. reported top-line results from its Phase 2b trial of oral MRGPRX2 antagonist EVO756 in moderate-to-severe chronic spontaneous urticaria. The randomized, double-blind, placebo-controlled study in 160 antihistamine-refractory patients did not meet the primary endpoint of change in Urticaria Activity Score over seven days at 12 weeks at any dose.
Based on these data, Evommune plans to cease development of EVO756 for chronic spontaneous urticaria, but will continue evaluating the drug in other indications. The company remains on track to report Phase 2b data for EVO756 in atopic dermatitis in the third quarter of 2026 and has begun a Phase 2b trial in migraine prophylaxis.
Evommune also highlighted positive Phase 2a proof-of-concept data in atopic dermatitis for its IL-18BP fusion protein EVO301, and stated it has a strong cash position supporting anticipated operations through 2028, which it believes will allow continued advancement of its inflammatory disease pipeline.
Evommune, Inc. Chief of Development Operations Janice Suzann Drew exercised stock options and sold shares in a planned trade. On June 22, 2026, she exercised options to acquire a total of 20,000 shares of common stock at exercise prices of $2.99 and $3.84 per share, then sold 20,000 shares in an open-market transaction at a weighted average price of $22.63 per share.
The filing notes that these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 9, 2026, indicating they were scheduled in advance. Footnotes also describe a standard multi-year vesting schedule for the underlying employee stock options.
Evommune, Inc. Chief Scientific Officer Jeegar Pravinkumar Patel executed an option exercise and related share sale in Evommune (EVMN) stock. On June 22, 2026, he exercised 1,488 employee stock options at $3.84 per share and sold 1,488 common shares in an open-market transaction at $22.50 per share. Following these transactions, he directly holds 46,403 shares of common stock and 27,842 employee stock options, which are scheduled to vest over time and expire on May 11, 2033. The filing notes that the trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2026, indicating the timing was set in advance.
Evommune, Inc. director and President & CEO Luis C. Pena reported an open-market sale of 7,438 shares of common stock on June 22, 2026 at a weighted average price of $22.71 per share. The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 2, 2026, indicating they were scheduled in advance. Following this sale, Pena directly holds 630,458 shares of Evommune common stock, so the sale represents only a small portion of his overall stake.